European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

EAU15: Future of targeted prostate cancer treatment

Sat, 21 Mar 2015

As treatment options become more refined and comprehensive, the tools available to the urologist or clinical oncologist to effectively target this treatment become more important. Systems that give precision on a molecular level are becoming a reality.

A substantial part of the second day of the Annual EAU Congress was devoted to the Section Meeting of the EAU Section of Oncological Urology, which cooperated with EORTC-GUCG, the EUOG, ESSO and ESTRO.

Profs. Freddie Hamdy (GB) and Morten Høyer (DK) gave back-to-back State-of-the-art lectures that together painted a poignant picture of the (very near) future for precisely-targeted treatment: surgical and radiotherapeutic, respectively. Key to both talks was the need for better targeting.

Hamdy showed the novel techniques of a prototype optical system that was developed in Oxford, which combined white-light with infrared in real time. Combined with the use of molecular mini-bodies, very precise surgical procedures can be achieved. He showed the size and scope of the team, which included engineers and radiologists. Hamdy: “We worked with a broad team to realize this project, but it’s the urologist who knows the unmet needs of patients.”

Speaking as a clinical oncologist on behalf of ESTRO, Høyer discussed the inclusion of pelvic lymph nodes in radiotherapy for prostate and bladder cancer. “The efficacy of elective radiation therapy to pelvic lymph nodes in therapy for PCa has not been proven in randomized clinical trials, and results from retrospective cohort studies are diverging. However, this poor efficacy could be explained by insufficient imaging, radiation techniques and dose.”

Speaking after the session, Høyer agreed that the optical system of Hamdy’s team would be very useful, combined with radiation oncology. “Combined, this could be the future of radio oncology and surgical oncology. What we need is better targeting of our treatments, defining volumes that we are treating with surgery or radiation oncology.”

“Although I’m well aware that I’m at a congress for urologists, it’s not a competition, there’s a mission for both of us. For instance, it would be obvious to treat patients with lymphnode metastasis with radiation oncology. That’s because we can treat electively, relatively large margins, which is not possible with surgery. We can boost up, give more intensive treatment of high-risk volumes, or volumes where we know there is metastasis.”

Asked about the multidisciplinary approach that is often mentioned in the treatment of urological cancers, Høyer quipped: “You shouldn’t just talk about it, but live together in the same house! Our new hospital in Aarhus, which opens in 2018, will be a single PCa clinic with every discipline under the same roof. I hope to see clinics like this across Europe in the near future!”

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer